



Ref: FOIA Reference 2022/23-333

Date: 29th September 2022

Email foi@uhnm.nhs.uk

Dear

I am writing in response to your emails dated 19th September 2022 requesting information under the Freedom of Information Act (2000) regarding Biologic medicine and Haemophilia A.

The section 12 exemption states:

The authority can combine related requests received within a period of 60 consecutive days from:

- The same person or
- People who appear to be acting in concert or in pursuance of a campaign.

As of 1st November 2014 University Hospitals of North Midlands NHS Trust (UHNM) manages two hospital sites – Royal Stoke University Hospital, and County Hospital (Stafford). Therefore the response below is for the two sites combined from that date where appropriate.

Request #1

Q1 I have a freedom of information query regarding the use of Biologic medicines in Dermatology. Could you please answer the following two questions?

How many patients were treated in the last 3 months by the Dermatology department (for any medical condition) with the following biologic drugs:

- **Abatacept**
- **Adalimumab - Humira**
- **Adalimumab Biosimilar**
- **Apremilast**
- **Bimekizumab**
- **Brodalumab**
- **Certolizumab**
- **Dimethyl fumarate**
- **Etanercept - Enbrel**
- **Etanercept Biosimilar**
- **Golimumab**
- **Guselkumab**
- **Infliximab - Remicade**
- **Infliximab Biosimilar**

- **Ixekizumab**
- **Risankizumab**
- **Secukinumab**
- **Tildrakizumab**
- **Tofacitinib**
- **Ustekinumab**
- **Upadacitinib**

A1 We are unable to provide the information you require in the requested format as to release this data could lead to the identification of the person(s) involved due to the low numbers involved, and would breach the Trusts obligations under Data Protection Act 2018. Accordingly, this aspect of your request is exempt from disclosure under the terms of Section 40(2) of the FOI Act. *Personal information*. However as the Trust is committed to openness and transparency we can band the numbers as being <5

This exemption is an absolute exemption and therefore no consideration of the public interest test is needed.

- Abatacept = 0
- Adalimumab – Humira =7
- Adalimumab Biosimilar = 100
- Apremilast = 0
- Bimekizumab = 0
- Brodalumab = 0
- Certolizumab = 0
- Dimethyl fumarate =<5
- Etanercept – Enbrel =<5
- Etanercept Biosimilar =<5
- Golimumab = 0
- Guselkumab =<5
- Infliximab – Remicade = 0
- Infliximab Biosimilar - 0
- Ixekizumab =<5
- Risankizumab =<5
- Secukinumab = 33
- Tildrakizumab = 0
- Tofacitinib = 0
- Ustekinumab = 43
- Upadacitinib = 0

Q2 How many patients were treated in the last 3 months by the Dermatology department for Psoriatic Arthritis (PsA) ONLY with the following biologic drugs:

- **Adalimumab - Humira**
- **Adalimumab Biosimilar**
- **Apremilast**
- **Certolizumab**
- **Dimethyl fumarate**
- **Etanercept - Enbrel**
- **Etanercept Biosimilar**
- **Guselkumab**

- **Infliximab - Remicade**
- **Infliximab Biosimilar**
- **Ixekizumab**
- **Risankizumab**
- **Secukinumab**
- **Ustekinumab**

A2 We are unable to provide the information you require in the requested format as to release this data could lead to the identification of the person(s) involved due to the low numbers involved, and would breach the Trusts obligations under Data Protection Act 2018. Accordingly, this aspect of your request is exempt from disclosure under the terms of Section 40(2) of the FOI Act. Personal information. However as the Trust is committed to openness and transparency we can band the numbers as being <5

This exemption is an absolute exemption and therefore no consideration of the public interest test is needed.

- Adalimumab – Humira = <5
- Adalimumab Biosimilar = 0
- Apremilast = 0
- Certolizumab = 0
- Dimethyl fumarate = 0
- Etanercept – Enbrel = 0
- Etanercept Biosimilar = 0
- Guselkumab = 0
- Infliximab – Remicade = 0
- Infliximab Biosimilar = 0
- Ixekizumab = 0
- Risankizumab = 0
- Secukinumab - 0
- Ustekinumab = 0

Request #2

Q1 I am analysing the incidence and treatment of Haemophilia A. Could you kindly provide answers to the following questions.

In the last three months, how many patients have been treated by your haemophilia centre with the following products?

- **Advate**
- **Adynovi**
- **Elocta**
- **Esperoct**
- **Factor Eight Inhibitor Bypass Activity (FEIBA)**
- **Hemlibra (standalone)**
- **Hemlibra in combination with any Factor VIII**
- **NovoEight**
- **NovoSeven RT**
- **Obizur**

- **Refacto AF**

A1 We are unable to provide the information you require in the requested format as to release this data could lead to the identification of the person(s) involved due to the low numbers involved, and would breach the Trusts obligations under Data Protection Act 2018. Accordingly, this aspect of your request is exempt from disclosure under the terms of Section 40(2) of the FOI Act. Personal information. However as the Trust is committed to openness and transparency we can band the numbers as being <5

This exemption is an absolute exemption and therefore no consideration of the public interest test is needed.

- <5 = Advate
- <5 = FEIBA
- <5 = ELOCTA

Q2 In the last three months, how many patients were treated with the following products for severe Haemophilia A ONLY?

- **Advate**
- **Adynovi**
- **Elocta**
- **Esperoct**
- **Factor Eight Inhibitor Bypass Activity (FEIBA)**
- **Hemlibra (standalone)**
- **Hemlibra in combination with any Factor VIII**
- **NovoEight**
- **NovoSeven RT**
- **Obizur**
- **Refacto AF**

A21 We are unable to provide the information you require in the requested format as to release this data could lead to the identification of the person(s) involved due to the low numbers involved, and would breach the Trusts obligations under Data Protection Act 2018. Accordingly, this aspect of your request is exempt from disclosure under the terms of Section 40(2) of the FOI Act. *Personal information*. However as the Trust is committed to openness and transparency we can band the numbers as being <5

This exemption is an absolute exemption and therefore no consideration of the public interest test is needed.

Advate is used for home delivery
Prophylaxi is not at the centre
<5 Hemlibra (standalone) home delivery and not at the centre

*Please note that any individuals identified do not give consent for their personal data to be processed for the purposes of direct marketing.

UHNM NHS Trust is a public sector body and governed by EU law. FOI requestors should note that any new Trust requirements over the EU threshold will be subject to these regulations and will be advertised for open competition accordingly.

Where the Trust owns the copyright in information provided, you may re-use the information in line with the conditions set out in the Open Government Licence v3 which is available at <http://www.nationalarchives.gov.uk/doc/open-government-licence/version/3/>. Where information was created by third parties, you should contact them directly for permission to re-use the information.

An anonymised copy of this request can be found on the Trust's disclosure log, please note that all requests can be found at the following link: <http://www.uhnm.nhs.uk/aboutus/Statutory-Policies-and-Procedures/Pages/Freedom-of-Information-Disclosure-Log.aspx>

This letter confirms the completion of this request. A log of this request and a copy of this letter will be held by the Trust.

If you have any queries related to the response provided please in the first instance contact my office.

Should you have a complaint about the response or the handling of your request, please also contact my office to request a review of this. If having exhausted the Trust's FOIA complaints process you are still not satisfied, you are entitled to approach the Information Commissioner's Office (ICO) and request an assessment of the manner in which the Trust has managed your request.

The Information Commissioner may be contacted at:

Information Commissioner's Office, Wycliffe House, Water Lane, Wilmslow, Cheshire SK9 5AF or via www.ico.org.uk.

If following review of the responses I can be of any further assistance please contact my secretary on 01782 671612.

Yours,



Leah Carlisle
Head of Data, Security & Protection/ Data Protection Officer